D.A. Davidson & CO. Has $638,000 Position in Inari Medical, Inc. (NASDAQ:NARI)

D.A. Davidson & CO. raised its position in Inari Medical, Inc. (NASDAQ:NARI) by 7.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 12,491 shares of the company’s stock after acquiring an additional 892 shares during the quarter. D.A. Davidson & CO.’s holdings in Inari Medical were worth $638,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. R Squared Ltd acquired a new stake in Inari Medical in the fourth quarter valued at $45,000. KBC Group NV lifted its stake in shares of Inari Medical by 39.0% during the 3rd quarter. KBC Group NV now owns 1,774 shares of the company’s stock worth $73,000 after buying an additional 498 shares during the last quarter. Covestor Ltd lifted its stake in shares of Inari Medical by 63.5% during the 3rd quarter. Covestor Ltd now owns 2,384 shares of the company’s stock worth $99,000 after buying an additional 926 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of Inari Medical by 66.8% during the 4th quarter. GAMMA Investing LLC now owns 1,963 shares of the company’s stock worth $100,000 after buying an additional 786 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. lifted its stake in shares of Inari Medical by 44.2% during the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,113 shares of the company’s stock worth $128,000 after buying an additional 954 shares during the last quarter. Institutional investors and hedge funds own 90.98% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. Piper Sandler raised their target price on shares of Inari Medical from $52.00 to $80.00 and gave the stock a “neutral” rating in a research note on Tuesday, January 7th. Oppenheimer assumed coverage on shares of Inari Medical in a research note on Tuesday, December 17th. They set an “outperform” rating and a $75.00 target price for the company. William Blair restated a “market perform” rating on shares of Inari Medical in a research note on Tuesday, January 7th. Truist Financial raised their target price on shares of Inari Medical from $50.00 to $63.00 and gave the stock a “hold” rating in a research note on Wednesday, December 18th. Finally, Canaccord Genuity Group reissued a “hold” rating and issued a $80.00 price objective (up previously from $74.00) on shares of Inari Medical in a report on Tuesday, January 7th. Twelve equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $68.00.

Insider Activity

In other news, Director William Hoffman sold 60,000 shares of the business’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $55.66, for a total value of $3,339,600.00. Following the completion of the transaction, the director now directly owns 441,233 shares in the company, valued at approximately $24,559,028.78. The trade was a 11.97 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Andrew Hykes sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $55.29, for a total transaction of $165,870.00. Following the completion of the transaction, the chief executive officer now owns 439,310 shares of the company’s stock, valued at $24,289,449.90. The trade was a 0.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 263,000 shares of company stock worth $15,599,470. 10.60% of the stock is currently owned by corporate insiders.

Inari Medical Trading Up 0.1 %

Shares of NASDAQ:NARI opened at $79.97 on Tuesday. The firm has a 50 day moving average of $71.96 and a 200-day moving average of $55.76. The stock has a market capitalization of $4.68 billion, a PE ratio of -59.24 and a beta of 1.02. Inari Medical, Inc. has a 12 month low of $36.73 and a 12 month high of $79.99.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.